Pfizer (NYSE:PFE) Trading Down 1.5% – Time to Sell?

Pfizer Inc. (NYSE:PFE)’s stock price dropped 1.5% on Tuesday . The stock traded as low as $24.72 and last traded at $24.97. Approximately 11,670,036 shares changed hands during trading, a decline of 74% from the average daily volume of 44,726,215 shares. The stock had previously closed at $25.34.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

The company has a market cap of $140.26 billion, a P/E ratio of 17.54, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company’s fifty day moving average is $25.98 and its 200 day moving average is $26.83. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PFE. United Bank boosted its holdings in shares of Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 1,277 shares in the last quarter. HighTower Advisors LLC grew its stake in shares of Pfizer by 5.2% in the third quarter. HighTower Advisors LLC now owns 3,219,490 shares of the biopharmaceutical company’s stock worth $93,146,000 after acquiring an additional 157,775 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Pfizer by 0.5% during the third quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock valued at $15,348,000 after acquiring an additional 2,600 shares in the last quarter. Investment Management Corp of Ontario raised its holdings in Pfizer by 49.4% in the third quarter. Investment Management Corp of Ontario now owns 188,144 shares of the biopharmaceutical company’s stock worth $5,445,000 after buying an additional 62,200 shares during the last quarter. Finally, Integrated Wealth Concepts LLC raised its holdings in Pfizer by 12.1% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 488,757 shares of the biopharmaceutical company’s stock worth $14,145,000 after acquiring an additional 52,662 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.